Advertisement

IRAKLIA Trial of Isatuximab via On-Body Injector in Multiple Myeloma
Posted: 09/19/2025 | By: Custom Content

Subcutaneous administration of isatuximab via an on-body injector (OBI) offers potential advantages over intravenous (IV) infusions. Take this quiz to test your understanding of a recent study published in Journal of Clinical Oncology on this novel administration technique.

Question 1 of 5

What was the primary objective of the IRAKLIA study?

Choose 1

A
To compare isatuximab vs daratumumab in newly diagnosed multiple myeloma
B
To assess whether subcutaneous isatuximab administered via an on-body injector (OBI) is noninferior to intravenous (IV) isatuximab in patients with relapsed/refractory multiple myeloma
C
To evaluate carfilzomib plus isatuximab in patients with transplant-eligible multiple myeloma
D
To evaluate isatuximab OBI in patients with primary refractory multiple myeloma

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage